Salcedo Mila Pontremoli, Milbourne Andrea M, Jhingran Anuja, Eifel Patricia J, Ramirez Pedro T, Schmeler Kathleen M
Department of Gynecology and Obstetrics, Federal University of Health Sciences/Irmandade Santa Casa de Misericórdia de Porto Alegre, Brazil.
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Tex., USA.
Case Rep Oncol. 2015 May 6;8(2):217-21. doi: 10.1159/000382117. eCollection 2015 May-Aug.
The standard treatment for locally advanced cervical cancer is chemoradiation, with the majority of patients having a complete response to the therapy. The current surveillance recommendations from the Society of Gynecologic Oncology include annual cytology, with a small proportion of patients subsequently diagnosed with high-grade cervical dysplasia (CIN 2/3). To date, there is limited information regarding the optimal treatment and outcome for patients diagnosed with CIN 2/3. The current report describes the diagnosis, management and outcome of 4 patients diagnosed with CIN 2/3 following chemoradiation.
We describe 4 patients who developed CIN 2/3 seven months to 8 years following radiation therapy for locally advanced cervical cancer. All 4 patients were asymptomatic and the abnormalities were first detected by a Pap test. Three of the patients were managed conservatively with observation, and the CIN 2/3 resolved without intervention. One patient underwent 2 cervical conizations followed by a hysterectomy with no residual dysplasia noted on the hysterectomy specimen.
The majority of patients with recurrent cervical cancer after chemoradiation are symptomatic, and most cases are detected by a physical examination. The role of cytology, colposcopy and biopsies may be of limited value. Furthermore, the significance of the diagnosis of CIN 2/3 in patients previously treated with radiation therapy was not associated with recurrent disease in the 4 patients described. Our results suggest that cytology may be of limited value in detecting recurrence in patients following radiation therapy, even when CIN 2/3 is detected.
局部晚期宫颈癌的标准治疗方法是放化疗,大多数患者对该疗法有完全反应。妇科肿瘤学会目前的监测建议包括每年进行细胞学检查,一小部分患者随后被诊断为高级别宫颈发育异常(CIN 2/3)。迄今为止,关于诊断为CIN 2/3的患者的最佳治疗方法和预后的信息有限。本报告描述了4例放化疗后诊断为CIN 2/3的患者的诊断、管理和预后情况。
我们描述了4例局部晚期宫颈癌放疗后7个月至8年发生CIN 2/3的患者。所有4例患者均无症状,异常情况最初通过巴氏试验检测到。其中3例患者采取保守观察治疗,CIN 2/3未经干预自行消退。1例患者接受了2次宫颈锥切术,随后进行了子宫切除术,子宫切除标本上未发现残留发育异常。
大多数放化疗后复发性宫颈癌患者有症状,大多数病例通过体格检查发现。细胞学检查、阴道镜检查和活检的作用可能有限。此外,在我们描述的4例患者中,先前接受放疗的患者诊断为CIN 2/3与复发性疾病无关。我们的结果表明,即使检测到CIN 2/3,细胞学检查在检测放疗后患者复发方面的价值可能有限。